Aldurazyme
Mucopolysaccharidosis Type 1
Genzyme, a Sanofi CompanyUNKNOWNPhase 4 / ApprovedDormant
A
84/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 77/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Mucopolysaccharidosis Type 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Iduronidase, .Alpha.-L-(8-Histidine) (Human) University of California, San Francisco | Phase 4 | BBB |
Valanafusp Alfa ArmaGen, Inc | Phase 1/2 | BB |
Rhidu Genzyme, a Sanofi Company | Phase 3 | BB |
Serostim Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 2/3 | B |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 15 →
Same molecule, other indications
Aldurazyme is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →